Latest Iovance Biotherapeutics News & Updates

See the latest news and media coverage for Iovance. We track all announcements, press releases, and industry mentions in real time, all in one place.

Iovance Biotherapeutics (Iovance)

Biopharmaceutical company developing tumor-infiltrating lymphocyte therapies

iovance.com

Headquarters: San Carlos, United States
Founded year: 2007
Company type: Public company
Number of employees: 900–1,000
Industry: Pharmaceuticals

Last updated Today

Latest news about Iovance Biotherapeutics (Iovance)

In short: Iovance reported strong Q2 results and secured Australian approval for Amtagvi, despite facing a shareholder class action lawsuit.

Company announcements

July 30 Iovance

Iovance announces Q2 2026 conference call and webcast

The call on August 6, 2026, at 8:30 a.m. ET will discuss quarterly business performance and recent developments. A live and archived webcast will be available on the company's website.

June 23 Iovance

Iovance highlights Dr. Thomas's perspective on melanoma planning

He emphasizes that earlier planning may change treatment journeys for BRAF-mutated melanoma patients who have progressed, viewing innovation as a better process beyond new therapies.

June 5 Iovance

Iovance gets IND clearance for IOV-5001 and Australian approval

The company also highlighted its presence at ASCO26 and the Jefferies Healthcare conference, underscoring momentum in cell therapy.

June 4 Iovance

Iovance executives present at Jefferies Global Healthcare Conference

Interim CEO Fred Vogt and CFO Corleen Roche will speak at 1:25 p.m. ET. A live webcast and replay will be available.

Media coverage

Yesterday Yahoo Finance

IOVA Q2 Earnings Beat, Stock Jumps 43% on Strong Amtagvi Uptake

Iovance rises 43% after Q2 results top estimates as Amtagvi sales beat forecasts, boosting revenues and prompting a review of full-year guidance.

Yesterday Barron's

IOVA | Iovance Biotherapeutics Inc. Stock Overview (U.S.: Nasdaq) | Barron s

Complete Iovance Biotherapeutics Inc. stock information by Barron's. View real-time IOVA stock price...

July 30 The National Law Review

Class Action Lawsuit Filed Against Iovance Biotherapeutics, Inc. (IOVA) - Recover Losses - Contact Levi & Korsinsky Before July 14, 2025

Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates. THE LAWSUIT: A class action securities...

July 16 TechStock²

Iovance shares surge as attention shifts to Amtagvi’s second-half sales target

Iovance Biotherapeutics NASDAQ:IOVA gained 10.2% between July 10 and the close on Thursday.

Never miss news about Iovance

Track Iovance and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.